Review our commercial product billing guide
Dec. 2023Important Notices
Pennsylvania Act 1 of 2023, signed into law this May, requires insurance policies to cover all costs associated with one supplemental breast screening every year for women with increased risk of breast cancer via MRI or ultrasound.
To assist providers in navigating this new law, we are offering recommendations as a guide to aid with compliance.
We encourage you to review our commercial product billing guide for recommendations around complying with Pennsylvania Act 1 of 2023.
If you have any questions or concerns, please contact your physician account executive or call Provider Services at 1-866-918-1595.
To assist providers in navigating this new law, we are offering recommendations as a guide to aid with compliance.
We encourage you to review our commercial product billing guide for recommendations around complying with Pennsylvania Act 1 of 2023.
If you have any questions or concerns, please contact your physician account executive or call Provider Services at 1-866-918-1595.
Recent Announcements
Voluntary nationwide recall: Ocaliva (Intercept – September)
Intercept Pharmaceuticals, Inc. is voluntarily withdrawing Ocaliva® (obeticholic acid) from the market. Ocaliva is used to treat a rare liver disease called primary biliary cholangitis (PBC).Oct. 2025Pharmacy Updates
HelpScript service helps patients enroll in manufacturer copay assistance programs
End-to-end provider support helps ensure a smooth submission processOct. 2025Important Notices
Important announcement – Telehealth submissions
As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.Sep. 2025Important Notices